Tropisetron

Overview

Tropisetron is a serotonin 5-HT₃ receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.[1] WP

It was patented in 1982 and approved for medical use in 1992. Tropisetron is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is sold by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the US. It is also available from Novell Pharmaceutical Laboratories and sold in several Asian countries as Setrovel.[2][3] WP

Risks and side effects

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. Hypotension, transient liver enzyme elevation, immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.[4–7] WP

Pharmacology

Pharmacology

Tropisetron acts as both a selective 5-HT₃ receptor antagonist and α₇-nicotinic receptor partial agonist.[8][9] WP

Tropisetron have been shown to sensitise human α₇-nicotinic receptors to low concentrations of acetylcholine, indicative of a possible co-agonist or other modulatory action of tropisetron at these receptors.[10] WP

Chemistry

Formula

C17H20N2O2 PC

Molar mass (g/mol)

284.35 PC

IUPAC name (computed by PubChem)

[(1S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate PC

SMILES

CN1[C@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43 PC

InChIKey

ZNRGQMMCGHDTEI-RYUDHWBXSA-N PC

PubChem CID

72165

IUPAC name

(1R,5S)-8-methyl-8-azabicyclo WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Müller W, Stratz T. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron. Scandinavian Journal of Rheumatology. Supplement. 2004. doi:10.1080/03009740410007032 · PMID 15515413
2. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
3. Other The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025
4. Journal / agency Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. The Oncologist. 2002. doi:10.1634/theoncologist.7-5-424 · PMID 12401905
5. Journal / agency Abali H, Celik I. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Investigation. 2007. doi:10.1080/07357900701208709 · PMID 17530482
6. Journal / agency Kovac AL. Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting. Drugs. December 2016. doi:10.1007/s40265-016-0663-3 · PMID 27988869
7. Journal / agency Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmöller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. Journal of Clinical Oncology. 2002-06-15. doi:10.1200/JCO.2002.09.064 · PMID 12065557
8. Journal / agency Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, Tran O, Wright N, Gordon JC. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorganic & Medicinal Chemistry Letters. February 2001. doi:10.1016/S0960-894X(00)00670-3 · PMID 11212100
9. Journal / agency Cui R, Suemaru K, Li B, Kohnomi S, Araki H. Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors. European Journal of Pharmacology. May 2009. doi:10.1016/j.ejphar.2008.12.051 · PMID 19374878
10. Journal / agency Callahan PM, Bertrand D, Bertrand S, Plagenhoef MR, Terry AV. Tropisetron sensitizes α7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals. Neuropharmacology. May 2017. doi:10.1016/j.neuropharm.2017.02.025 · PMID 28259598

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.